Literature DB >> 20117226

Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.

Ines A Silva1, Krystyna Olkiewicz, David Askew, Jacquelyn M Fisher, Meghana N Chaudhary, Kevin M Vannella, Daphne T Deurloo, Sung W Choi, Elizabeth M Pierce, Shawn G Clouthier, Chen Liu, Kenneth R Cooke.   

Abstract

Graft-versus-host disease (GVHD) remains the major complication of allogeneic bone marrow transplantation (allo-BMT). GVHD fundamentally depends upon the activation of donor T cells by host antigen-presenting cells (APCs), but the precise location of these interactions remains uncertain. We examined the role of secondary lymphoid organs (SLO) in the induction of GVHD by using homozygous aly/aly mice that are deficient in lymph nodes (LNs) and Peyer's patches (PPs). Lethally irradiated, splenectomized, aly/aly (LN/PP/Sp-/-) mice and sham-splenectomized, aly/+ (LN/PP/Sp+/+) mice received BMT from either syngeneic (aly/aly) or allogeneic, major histocompatibility complex (MHC) disparate donors. Surprisingly, although LN/PP/Sp-/- allo-BMT recipients experience a survival advantage, they developed significant systemic and target organ GVHD that is comparable to LN/PP/Sp+/+ controls. Early after allo-BMT, the activation and proliferation of donor T cells was significantly greater in the BM cavity of LN/PP/Sp-/- mice compared to LN/PP/Sp+/+ controls. Donor T cells in LN/PP/Sp-/- mice demonstrated cytolytic activity in vitro, but Graft vs Leukemia (GVL) activity could be overcome by increasing the tumor burden. These data suggest that SLO contribute to, but are not required for, allogeneic T cell responses, and suggest that the BM may represent an alternative, albeit less efficient site for T cell activation following allo-BMT. Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20117226      PMCID: PMC3838892          DOI: 10.1016/j.bbmt.2009.12.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  44 in total

1.  Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase.

Authors:  T Yamada; T Mitani; K Yorita; D Uchida; A Matsushima; K Iwamasa; S Fujita; M Matsumoto
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Authors:  K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation.

Authors:  T R Ziegler; A Panoskaltsus-Mortari; L H Gu; C R Jonas; C L Farrell; D L Lacey; D P Jones; B R Blazar
Journal:  Transplantation       Date:  2001-10-27       Impact factor: 4.939

4.  The alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing.

Authors:  J W Homeister; A D Thall; B Petryniak; P Malý; C E Rogers; P L Smith; R J Kelly; K M Gersten; S W Askari; G Cheng; G Smithson; R M Marks; A K Misra; O Hindsgaul; U H von Andrian; J B Lowe
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

5.  Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease.

Authors:  B Li; J Y New; E H Yap; J Lu; S H Chan; H Hu
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

6.  Acute graft-versus-host disease does not require alloantigen expression on host epithelium.

Authors:  Takanori Teshima; Rainer Ordemann; Pavan Reddy; Svetlana Gagin; Chen Liu; Kenneth R Cooke; James L M Ferrara
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

7.  Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation.

Authors:  K R Cooke; G R Hill; A Gerbitz; L Kobzik; T R Martin; J M Crawford; J P Brewer; J L Ferrara
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

8.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

9.  Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Authors:  Erin Gatza; Craig Y Okada
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes.

Authors:  G Smithson; C E Rogers; P L Smith; E P Scheidegger; B Petryniak; J T Myers; D S Kim; J W Homeister; J B Lowe
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  5 in total

1.  In vivo dynamics of T cells and their interactions with dendritic cells in mouse cutaneous graft-versus-host disease.

Authors:  Sarah Morin-Zorman; Christian Wysocki; Jieqing Zhu; Hongmei Li; Sylvain Zorman; Catherine Matte-Martone; Edwina Kisanga; Jennifer McNiff; Dhanpat Jain; David Gonzalez; David M Rothstein; Fadi G Lakkis; Ann Haberman; Warren D Shlomchik
Journal:  Blood Adv       Date:  2019-07-23

2.  Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.

Authors:  Jeffery J Auletta; Saada K Eid; Patiwet Wuttisarnwattana; Ines Silva; Leland Metheny; Matthew D Keller; Rocio Guardia-Wolff; Chen Liu; Fangjing Wang; Theodore Bowen; Zhenghong Lee; Luis A Solchaga; Sudipto Ganguly; Megan Tyler; David L Wilson; Kenneth R Cooke
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

3.  Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.

Authors:  M Y Shapira; A Klimov; S Vipul; S Grisariu; B R Avni; R Or; A I Bloom
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

Review 4.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

5.  Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation.

Authors:  Fangjing Wang; Saada Eid; James E Dennis; Kenneth R Cooke; Jeffery J Auletta; Zhenghong Lee
Journal:  J Stem Cells Regen Med       Date:  2015-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.